fire-4: evaluation of 1l efficacy of folfiri/cetuximab in patients with ras-wt mcrc
Published 1 year ago • 261 plays • Length 2:11Download video MP4
Download video MP3
Similar videos
-
3:07
fire-4: influence of baseline liquid biopsy results in 1l efficacy of folfiri/cetux in ras-wt mcrc
-
3:41
liquid biopsy results in treatment efficacy of folfiri/cetuximab in patients with tissue ras-wt mcrc
-
2:45
1l folfoxiri plus cetuximab or bevacizumab for ras wild-type mcrc
-
2:00
ermes: folfiri/cetuximab followed by cetuximab inferior to soc in ras & braf wt mcrc
-
4:25
fire-4.5: folfoxiri plus either bevacizumab or cetuximab in mcrc
-
1:24
fire-4.5: folfoxiri plus either bevacizumab or cetuximab as 1l treatment of braf v600e-mutant mcrc
-
1:49
fire-6: avelumab folfiri plus cetuximab followed by avelumab maintenance in untreated raswt mcrc
-
3:01
deeper: m-folfoxiri and cetuximab versus bevacizumab in mcrc
-
3:45
fire-3: cetuximab/folfiri prolongs metastatic colorectal cancer survival
-
1:04
deeper: folfoxiri cetuximab or bevacizumab for 1l mcrc
-
1:35
cricket and cave: cetuximab for the treatment of mcrc
-
8:37
cetuximab with xelox or xeliri is tolerable and effective in ras wild-type mcrc
-
4:16
fire-3 study: cetuximab versus bevacizumab in metastatic colorectal cancer
-
1:06
evaluating the role of cetuximab in metastatic colorectal cancer
-
1:45
breakwater: encorafenib plus cetuximab in patients with braf v600e-mutant mcrc
-
0:57
dr. peeters discusses the efficacy and safety of panitumumab versus cetuximab in colorectal cancer
-
2:11
pembrolizumab vs. chemo in first-line mcrc
-
1:08
dr. weinberg on the role of cetuximab in metastatic crc
-
2:21
profiling of brca mutations in colorectal cancer